Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss
Authors:
- 22 August 2013
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 25 (3) , 1151-1161
Abstract
In the present study, we evaluated the potential for aminobisphosphonates to enhance the development of bone-forming osteoblasts from progenitor cells isolated from aged female osteoporotic patients. The aminobisphosphonates tested significantly enhanced osteoblast formation and thus lend further insights into their possible mode of action in the treatment of osteoporosis. The primary aim of this study was to evaluate the influence of aminobisphosphonates on the osteogenesis of human bone marrow stromal cells (hBMSCs) and mineralization of differentiating bone-forming cells isolated from osteoporotic patients. The influence of aminobisphosphonate treatment on hBMSC osteogenesis was assessed by the quantitative measurement of alkaline phosphatase (ALP) activity, in addition to quantitative reverse transcription polymerase chain reaction and Western blot analysis of known osteogenic markers. Mineralized matrix formation by hBMSC-derived osteoblasts was visualized and quantified using Alizarin red staining. hBMSC cultures treated with osteogenic medium supplemented with zoledronate demonstrated a significant increase in Alizarin red staining after 3 weeks as compared to cells cultured in osteogenic medium alone. Similarly, cultures of differentiating hBMSCs isolated from patients receiving alendronate treatment also demonstrated an increased propensity for mineralization, even in the absence of further in vitro stimulation by zoledronate. The stimulatory effects of aminobisphosphonate treatment on hBMSC-derived osteoblast-mediated mineralization were independent of any alterations in ALP activity, although significant decreases in the expression levels of osteopontin (SPP1) were evident in hBMSCs following exposure to aminobisphosphonates. Further analysis including Western blotting and loss-of-function studies revealed osteopontin as having a negative influence on the mineralization of differentiating osteoporotic bone-forming cells. The results presented here demonstrate for the first time that aminobisphosphonate treatment of osteoporotic hBMSCs enhances their capacity for osteoblast formation and subsequent mineral deposition, thus supporting the concept of aminobisphosphonates as having an osteoanabolic effect in osteoporosis.Keywords
This publication has 52 references indexed in Scilit:
- The Transcriptional Profile of Mesenchymal Stem Cell Populations in Primary Osteoporosis Is Distinct and Shows Overexpression of Osteogenic InhibitorsPLOS ONE, 2012
- A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in miceBone, 2011
- Osteoporosis: now and the futureThe Lancet, 2011
- The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regenerationBiomaterials, 2010
- Cellular and Molecular Mechanisms of Bone RemodelingJournal of Biological Chemistry, 2010
- Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosisArthritis & Rheumatism, 2009
- Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiationBone, 2009
- Age‐related changes in Drosophila midgut are associated with PVF2, a PDGF/VEGF‐like growth factorAging Cell, 2008
- Defects in telomere maintenance molecules impair osteoblast differentiation and promote osteoporosisAging Cell, 2007
- Impaired Marrow Osteogenesis Is Associated With Reduced Endocortical Bone Formation but Does Not Impair Periosteal Bone Formation in Long Bones of SAMP6 MiceJournal of Bone and Mineral Research, 2005